6 Minutes Read | Listen to Article
Weight loss has been the holy grail of health goals since time immemorial — shaping not only how we look but also how we are perceived. It is part ambition, part lifelong pursuit, and entirely frustrating. Whether the motivation comes from a doctor’s advice or the mirror’s verdict, slimming down often sits at the very top of our to-do list. Yet stubborn body fat clings on with the persistence of an uninvited guest, refusing to budge without a fierce fight.
This is why quick-fix drugs like Ozempic and Mounjaro have shot to fame, promising rapid results. But the trade-off is steep: nausea, vomiting, and the abrupt end of any weight-loss momentum.
A research team from Syracuse University, led by chemistry professor Robert Doyle, may have found a gentler route. Instead of targeting the neurons in the brain’s hindbrain — the focus of most GLP-1 receptor agonists — they turned to the brain’s support cells, astrocytes. These cells naturally produce a peptide called octadecaneuropeptide (ODN), which reduces appetite and improves glucose control. ODN itself is not suitable for human use, so the team created a modified version, tridecaneuropeptide (TDN).
In trials on obese mice and musk shrews, TDN achieved weight loss and better blood sugar management — without nausea or vomiting. Doyle describes this as “starting the marathon halfway,” bypassing the early neural steps that cause unpleasant side effects.
The potential is enormous. TDN could replace or work alongside existing drugs at lower doses, making treatment more tolerable and sustainable. A biotech firm, CoronationBio, now holds the rights and plans human trials between 2026 and 2027.
If successful, this discovery could change the weight-loss game entirely — offering results without the misery, and making that elusive goal just a little more attainable.
**This news was published on Times of India on 12th August, 2025.
a Source Click
Green tea to lemon water: Harv...
Brain health: W...